{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:47:40Z","timestamp":1785422860744,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy originating from the adrenal cortex. These patients usually undergo chemotherapy with etoposide, doxorubicin, cisplatin and mitotane (EDP-M) in case of locally advanced or metastatic ACC. Computed tomography (CT) radiomics showed to be useful in adrenal pathologies. The study aimed to analyze the association between response to EDP-M treatment and CT textural features at diagnosis in patients with locally advanced or metastatic ACCs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We enrolled 17 patients with advanced or metastatic ACC who underwent CT before and after EDP-M therapy. The response to treatment was evaluated according to RECIST 1.1, Choi, and volumetric criteria. Based on the aforementioned criteria, the patients were classified as responders and not responders. Textural features were extracted from the biggest lesion in contrast-enhanced CT images with LifeX software. ROC curves were drawn for the variables that were significantly different (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Long-run high grey level emphasis (LRHGLE_GLRLM) and histogram kurtosis were significantly different between responder and not responder groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) and the multivariate ROC curve combining the two features showed a very good AUC (0.900; 95%IC: 0.724-1.000) in discriminating responders from not responders. More heterogeneous tissue texture of initial staging CT in locally advanced or metastatic ACC could predict the positive response to EDP-M treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Adrenal texture is able to predict the response to EDP-M therapy in patients with advanced ACC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-024-02476-2","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T05:01:50Z","timestamp":1728450110000},"page":"711-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Texture analysis can predict response to etoposide-doxorubicin-cisplatin in patients with adrenocortical carcinoma"],"prefix":"10.1007","volume":"48","author":[{"given":"Filippo","family":"Crim\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Turatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sussan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Iacobone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Torresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tizianel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Quaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Caccese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"issue":"11","key":"2476_CR1","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TMA Kerkhofs","year":"2013","unstructured":"Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM et al (2013) Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49(11):2579\u20132586. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034","journal-title":"Eur J Cancer"},{"issue":"5","key":"2476_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh Q, Clark OH, McMillan A (2006) Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: have we made Progress? World J Surg 30(5):872\u2013878. https:\/\/doi.org\/10.1007\/s00268-005-0329-x","journal-title":"World J Surg"},{"issue":"4","key":"2476_CR3","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol 179(4):G1\u2013G46. https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2476_CR4","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1476\u20131490. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099","journal-title":"Ann Oncol"},{"issue":"16","key":"2476_CR5","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.3390\/cancers14163904","volume":"14","author":"I Tizianel","year":"2022","unstructured":"Tizianel I, Caccese M, Torresan F et al (2022) The overall survival and progression-free survival in patients with Advanced Adrenocortical Cancer is increased after the Multidisciplinary Team evaluation. Cancers (Basel) 14(16):3904. https:\/\/doi.org\/10.3390\/cancers14163904","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2476_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","volume":"11","author":"M Terzolo","year":"2023","unstructured":"Terzolo M, Fassnacht M, Perotti P et al (2023) Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol 11(10):720\u2013730. https:\/\/doi.org\/10.1016\/S2213-8587(23)00193-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"2476_CR7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med 366(23):2189\u20132197. https:\/\/doi.org\/10.1056\/NEJMoa1200966","journal-title":"N Engl J Med"},{"issue":"5","key":"2476_CR8","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1148\/rg.2017170056","volume":"37","author":"MG Lubner","year":"2017","unstructured":"Lubner MG, Smith AD, Sandrasegaran K, Sahani DV, Pickhardt PJ (2017) CT texture analysis: definitions, applications, Biologic correlates, and challenges. Radiographics 37(5):1483\u20131503. https:\/\/doi.org\/10.1148\/rg.2017170056","journal-title":"Radiographics"},{"issue":"12","key":"2476_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12):749\u2013762. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141","journal-title":"Nat Rev Clin Oncol"},{"key":"2476_CR10","doi-asserted-by":"publisher","first-page":"101879","DOI":"10.1016\/j.tranon.2024.101879","volume":"41","author":"A Bose","year":"2024","unstructured":"Bose A, Datta S, Mandal R, Ray U, Dhar R (2024) Increased heterogeneity in expression of genes associated with cancer progression and drug resistance. Transl Oncol 41:101879. https:\/\/doi.org\/10.1016\/j.tranon.2024.101879","journal-title":"Transl Oncol"},{"issue":"1","key":"2476_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1102\/1470-7330.2013.0015","volume":"13","author":"B Ganeshan","year":"2013","unstructured":"Ganeshan B, Miles KA (2013) Quantifying tumour heterogeneity with CT. Cancer Imaging 13(1):140\u2013149. https:\/\/doi.org\/10.1102\/1470-7330.2013.0015","journal-title":"Cancer Imaging"},{"issue":"3","key":"2476_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.pan.2016.02.004","volume":"16","author":"C Verbeke","year":"2016","unstructured":"Verbeke C (2016) Morphological heterogeneity in ductal adenocarcinoma of the pancreas\u2013 does it matter? Pancreatology 16(3):295\u2013301. https:\/\/doi.org\/10.1016\/j.pan.2016.02.004","journal-title":"Pancreatology"},{"issue":"2","key":"2476_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.crad.2011.08.012","volume":"67","author":"B Ganeshan","year":"2012","unstructured":"Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K (2012) Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 67(2):157\u2013164. https:\/\/doi.org\/10.1016\/j.crad.2011.08.012","journal-title":"Clin Radiol"},{"issue":"3","key":"2476_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2214\/AJR.15.15864","volume":"207","author":"U Bashir","year":"2016","unstructured":"Bashir U, Siddique MM, Mclean E, Goh V, Cook GJ (2016) Imaging heterogeneity in Lung Cancer: techniques, applications, and challenges. Am J Roentgenol 207(3):534\u2013543. https:\/\/doi.org\/10.2214\/AJR.15.15864","journal-title":"Am J Roentgenol"},{"issue":"5","key":"2476_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s00330-014-3110-4","volume":"24","author":"C Yip","year":"2014","unstructured":"Yip C, Goh V, Davies A et al (2014) Assessment of Sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol 24(5):998\u20131005. https:\/\/doi.org\/10.1007\/s00330-014-3110-4","journal-title":"Eur Radiol"},{"key":"2476_CR16","doi-asserted-by":"publisher","unstructured":"Kim H, Park CM, Keam B et al (2017) The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors. Yang F, ed. PLoS One;12(11):e0187500. https:\/\/doi.org\/10.1371\/journal.pone.0187500","DOI":"10.1371\/journal.pone.0187500"},{"issue":"41","key":"2476_CR17","doi-asserted-by":"publisher","first-page":"e1753","DOI":"10.1097\/MD.0000000000001753","volume":"94","author":"HJ Yoon","year":"2015","unstructured":"Yoon HJ, Sohn I, Cho JH et al (2015) Decoding Tumor phenotypes for ALK, ROS1, and RET fusions in Lung Adenocarcinoma using a Radiomics Approach. Med (Baltim) 94(41):e1753. https:\/\/doi.org\/10.1097\/MD.0000000000001753","journal-title":"Med (Baltim)"},{"key":"2476_CR18","doi-asserted-by":"publisher","unstructured":"Tran K, Ginzburg D, Hong W, Attenberger U, Ko HS (2024) Post-radiotherapy stage III\/IV non-small cell lung cancer radiomics research: a systematic review and comparison of CLEAR and RQS frameworks. Eur Radiol. Published Online April 16. https:\/\/doi.org\/10.1007\/s00330-024-10736-1","DOI":"10.1007\/s00330-024-10736-1"},{"issue":"1","key":"2476_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bjsopen\/zraa061","volume":"5","author":"F Torresan","year":"2021","unstructured":"Torresan F, Crim\u00ec F, Ceccato F et al (2021) Radiomics: a new tool to differentiate adrenocortical adenoma from carcinoma. BJS open 5(1):1\u20137. https:\/\/doi.org\/10.1093\/bjsopen\/zraa061","journal-title":"BJS open"},{"key":"2476_CR20","doi-asserted-by":"publisher","unstructured":"Crim\u00ec F, Quaia E, Cabrelle G et al (2022) Diagnostic Accuracy of CT Texture Analysis in adrenal masses: a systematic review. Int J Mol Sci 23(2). https:\/\/doi.org\/10.3390\/ijms23020637","DOI":"10.3390\/ijms23020637"},{"issue":"3","key":"2476_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2214\/AJR.18.20097","volume":"212","author":"LM Ho","year":"2019","unstructured":"Ho LM, Samei E, Mazurowski MA et al (2019) Can texture analysis be used to Distinguish Benign from malignant adrenal nodules on unenhanced CT, contrast-enhanced CT, or In-Phase and opposed-phase MRI? AJR Am J Roentgenol 212(3):554\u2013561. https:\/\/doi.org\/10.2214\/AJR.18.20097","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"2476_CR22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.crad.2019.06.021","volume":"74","author":"MM Elmohr","year":"2019","unstructured":"Elmohr MM, Fuentes D, Habra MA et al (2019) Machine learning-based texture analysis for differentiation of large adrenal cortical tumours on CT. Clin Radiol 74(10):818. e1-818.e7","journal-title":"Clin Radiol"},{"key":"2476_CR23","unstructured":"Lysosafe Service. Accessed August 27 (2024) https:\/\/lysosafe.clinfile.com\/login"},{"key":"2476_CR24","doi-asserted-by":"crossref","unstructured":"Ceccato F, Crim\u00ec F (2024) Texture analysis can predict response to Etoposide-Doxorubicin-Cisplatin in patients with adrenocortical carcinoma. Accessed July 10, 2024. https:\/\/researchdata.cab.unipd.it\/id\/eprint\/1333","DOI":"10.1007\/s40618-024-02476-2"},{"issue":"2","key":"2476_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"8","key":"2476_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(18)30337-1","volume":"19","author":"G Bisogno","year":"2018","unstructured":"Bisogno G, Jenney M, Bergeron C et al (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19(8):1061\u20131071. https:\/\/doi.org\/10.1016\/S1470-2045(18)30337-1","journal-title":"Lancet Oncol"},{"issue":"13","key":"2476_CR27","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and Positron Emission Tomography in patients with metastatic gastrointestinal stromal tumor treated at a single Institution with Imatinib Mesylate: proposal of New Computed Tomography Response Criteria. J Clin Oncol 25(13):1753\u20131759. https:\/\/doi.org\/10.1200\/JCO.2006.07.3049","journal-title":"J Clin Oncol"},{"issue":"6","key":"2476_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/cancers12061395","volume":"12","author":"R Ambrosini","year":"2020","unstructured":"Ambrosini R, Balli MC, Lagan\u00e0 M et al (2020) Adrenocortical Carcinoma and CT Assessment of Therapy Response: the value of combining multiple criteria. Cancers (Basel) 12(6):1395. https:\/\/doi.org\/10.3390\/cancers12061395","journal-title":"Cancers (Basel)"},{"issue":"16","key":"2476_CR29","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S et al (2018) LIFEx: a freeware for Radiomic feature calculation in Multimodality Imaging to accelerate advances in the characterization of Tumor Heterogeneity. Cancer Res 78(16):4786\u20134789. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125","journal-title":"Cancer Res"},{"issue":"12","key":"2476_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.crad.2004.07.008","volume":"59","author":"G Castellano","year":"2004","unstructured":"Castellano G, Bonilha L, Li LM, Cendes F (2004) Texture analysis of medical images. Clin Radiol 59(12):1061\u20131069. https:\/\/doi.org\/10.1016\/j.crad.2004.07.008","journal-title":"Clin Radiol"},{"issue":"1","key":"2476_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12672-022-00577-z","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Fu Y, Yi X, Guan X, Liu L, Chen BT (2022) Application of radiomics in adrenal incidentaloma: a literature review. Discov Oncol 13(1):112. https:\/\/doi.org\/10.1007\/s12672-022-00577-z","journal-title":"Discov Oncol"},{"issue":"7","key":"2476_CR32","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00261-015-0438-4","volume":"40","author":"MG Lubner","year":"2015","unstructured":"Lubner MG, Stabo N, Lubner SJ et al (2015) CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging 40(7):2331\u20132337. https:\/\/doi.org\/10.1007\/s00261-015-0438-4","journal-title":"Abdom Imaging"},{"issue":"7467","key":"2476_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature12624","volume":"501","author":"CE Meacham","year":"2013","unstructured":"Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501(7467):328\u2013337. https:\/\/doi.org\/10.1038\/nature12624","journal-title":"Nature"},{"issue":"1","key":"2476_CR34","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2589-7500(21)00215-6","volume":"4","author":"L Feng","year":"2022","unstructured":"Feng L, Liu Z, Li C et al (2022) Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. Lancet Digit Heal 4(1):e8\u2013e17. https:\/\/doi.org\/10.1016\/S2589-7500(21)00215-6","journal-title":"Lancet Digit Heal"},{"issue":"2","key":"2476_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1148\/rg.282075068","volume":"28","author":"C Suzuki","year":"2008","unstructured":"Suzuki C, Jacobsson H, Hatschek T et al (2008) Radiologic measurements of Tumor response to treatment: practical approaches and limitations. Radiographics 28(2):329\u2013344. https:\/\/doi.org\/10.1148\/rg.282075068","journal-title":"Radiographics"},{"issue":"5","key":"2476_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40618-017-0775-y","volume":"41","author":"R Armignacco","year":"2018","unstructured":"Armignacco R, Cantini G, Canu L et al (2018) Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis. J Endocrinol Invest 41(5):499\u2013507. https:\/\/doi.org\/10.1007\/s40618-017-0775-y","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02476-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02476-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02476-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T10:28:05Z","timestamp":1740997685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02476-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02476-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained in all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and patient consent"}},{"value":"All authors declare that they have no conflicts of interest in this topic that might be perceived as influencing the impartiality of the reported research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}